Patient And Tumor Characteristics As Determinants Of Overall Survival (Os) In Braf V600 Mutant (Mt) Metastatic Colorectal Cancer (Mcrc) Treated With Doublet Or Triplet Targeted Therapy.

Javier Ros Montañá,Giulia Martini,Iosune Baraibar,Guillermo Villacampa,Raquel Comas,Davide Ciardiello,Ariadna Garcia,Xavier Hernandez Yague,Bernardo Queralt,Antonieta Salud Salvia,Guillem Argiles, Jose Luis Cuadra,Rodrigo A Toledo,Irene Chicote,Nuria Mulet,Ana Vivancos,Hector G. Palmer,Rodrigo Dienstmann,Josep Tabernero,Elena Elez

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 7|浏览44

暂无评分

摘要

4112Background: BRAF V600 mt mCRC is an aggressive disease with poor OS under standard chemotherapy. Treatment with doublet and triplet targeted combinations, such as BRAF inhibitor+ antiEGFR+/- ME...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要